Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $47.6, signifying a -5.52% move from its prior day's close.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Philip Morris International Inc. (PM) ...

Catterton—backed by luxury giant LVMH—has led an $800 million funding round for Flexjet, taking a roughly 20% stake that values the private jet company.

Microsoft has issued an urgent security alert this weekend after discovering attackers exploiting a critical zero‑day ...

Quest Diagnostics ranks first in Revenue Growth among its peers. It is second in Gross Profit and Return on Equity. The ...

In a cultural climate where the definition of masculinity is more complex than ever, men’s wellness brands are evolving to ...

Hims & Hers Health recurring revenue grew 111% YoY, boosted by personalization and chronic care. Forecasting $2.35B revenue ...

Getting a strong erection is a complicated physiological process that requires precise coordination of many body systems.

The overall sentiment of these big-money traders is split between 31% bullish and 50%, bearish. Out of all of the special options we uncovered, 3 are puts, for a total amount of $106,898, and 13 are ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Hims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want ...

An article in The Journal For Nurse Practitioners found that Depo-Testosterone was the most cost-efficient TRT option, and ...